[go: up one dir, main page]

CL2023000086A1 - Análogos de insulina novedosos y usos de estos(div 202201400) - Google Patents

Análogos de insulina novedosos y usos de estos(div 202201400)

Info

Publication number
CL2023000086A1
CL2023000086A1 CL2023000086A CL2023000086A CL2023000086A1 CL 2023000086 A1 CL2023000086 A1 CL 2023000086A1 CL 2023000086 A CL2023000086 A CL 2023000086A CL 2023000086 A CL2023000086 A CL 2023000086A CL 2023000086 A1 CL2023000086 A1 CL 2023000086A1
Authority
CL
Chile
Prior art keywords
div
insulin analogues
novel insulin
insulin
diabetes
Prior art date
Application number
CL2023000086A
Other languages
English (en)
Inventor
Hubalek Frantisek
Norrman Mathias
Birk Olsen Helle
Madsen Peter
Borglum Kjeldsen Thomas
Sturis Jeppe
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CL2023000086A1 publication Critical patent/CL2023000086A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención pertenece al campo terapéutico de los fármacos para las afecciones médicas relacionadas con la diabetes. Más específicamente, la invención se refiere a análogos de insulina de la insulina humana. La invención proporciona composiciones farmacéuticas que comprenden tales análogos de insulina y los usos de tales análogos para el tratamiento o prevención de afecciones médicas relacionadas con la diabetes.
CL2023000086A 2019-12-11 2023-01-09 Análogos de insulina novedosos y usos de estos(div 202201400) CL2023000086A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19215315 2019-12-11

Publications (1)

Publication Number Publication Date
CL2023000086A1 true CL2023000086A1 (es) 2023-08-04

Family

ID=68886882

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000086A CL2023000086A1 (es) 2019-12-11 2023-01-09 Análogos de insulina novedosos y usos de estos(div 202201400)

Country Status (29)

Country Link
US (3) US11498951B2 (es)
EP (2) EP4480492A3 (es)
JP (2) JP6995284B2 (es)
KR (1) KR102427426B1 (es)
CN (1) CN114787184A (es)
AR (1) AR120717A1 (es)
AU (1) AU2020402135A1 (es)
BR (1) BR112022009510A2 (es)
CA (1) CA3159114A1 (es)
CL (1) CL2023000086A1 (es)
CO (1) CO2022007273A2 (es)
DK (1) DK4073097T3 (es)
ES (1) ES2985989T3 (es)
FI (1) FI4073097T3 (es)
HR (1) HRP20241042T1 (es)
HU (1) HUE067827T2 (es)
IL (2) IL319162A (es)
LT (1) LT4073097T (es)
MA (1) MA58093B1 (es)
MX (2) MX2022006251A (es)
MY (1) MY208364A (es)
PE (1) PE20221260A1 (es)
PH (1) PH12022551094A1 (es)
PL (1) PL4073097T3 (es)
PT (1) PT4073097T (es)
RS (1) RS65822B1 (es)
SI (1) SI4073097T1 (es)
TW (1) TWI773009B (es)
WO (1) WO2021116292A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016311283B2 (en) 2015-08-25 2020-10-08 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
CN114787184A (zh) * 2019-12-11 2022-07-22 诺和诺德股份有限公司 新型胰岛素类似物及其用途
KR20230057686A (ko) 2021-10-22 2023-05-02 주식회사 엘지에너지솔루션 캡 어셈블리 및 이를 포함하는 이차 전지

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
ES2072596T3 (es) 1989-12-21 1995-07-16 Novo Nordisk As Preparaciones de insulina que contienen acido nicotinico o nicotinamida.
RO112873B1 (ro) 1993-09-17 1998-01-30 Novo Nordisk As Derivati de insulina
IL114160A (en) 1994-06-17 2006-12-31 Novo Nordisk As Dna constructs encoding heterologous proteins and processes for the heterologous protein production in yeast
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5922678A (en) 1996-06-28 1999-07-13 Eli Lilly And Company Methods for treating diabetes
WO1998028429A1 (en) 1996-12-20 1998-07-02 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
AU742591B2 (en) 1997-03-20 2002-01-10 Novo Nordisk A/S Zinc free insulin crystals for use in pulmonary compositions
PL340255A1 (en) 1997-10-24 2001-01-29 Lilly Co Eli Non-dissolving insulin compositions
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US7193035B2 (en) 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
ATE517119T1 (de) 2003-12-03 2011-08-15 Novo Nordisk As Einzelketteninsulin
WO2006097521A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Pegylated single-chain insulin
WO2007096431A1 (en) 2006-02-27 2007-08-30 Novo Nordisk A/S Insulin derivatives
EP1996709A2 (en) 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
ITRG20070003A1 (it) 2007-07-17 2009-01-18 Salvatore Lucifora Metodo e sistema informatico per analizzare le prestazioni e dimensionare una cella underlay/overlay di un sistema di telecomunicazione cellulare
EP2178909B1 (en) 2007-08-13 2015-10-21 Novo Nordisk A/S Rapid acting insulin analogues
EP2178910B1 (en) 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
CN101784562B (zh) 2007-08-15 2016-07-13 诺沃-诺迪斯克有限公司 具有酰基和亚烷基二醇部分的胰岛素类似物
EP2254905B1 (en) 2008-03-14 2016-12-14 Novo Nordisk A/S Protease-stabilized insulin analogues
KR101755434B1 (ko) 2008-03-18 2017-07-10 노보 노르디스크 에이/에스 프로테아제 안정화되고, 아실화된 인슐린 유사체
JP5818681B2 (ja) 2008-04-01 2015-11-18 ノボ・ノルデイスク・エー／エス インスリンアルブミンコンジュゲート
ES2611040T3 (es) 2009-06-30 2017-05-04 Novo Nordisk A/S Derivados de insulina
ES2552401T3 (es) 2009-11-02 2015-11-27 Novo Nordisk A/S Solución farmacéutica de albúmina unida no covalentemente e insulina acilada
JP5973427B2 (ja) 2010-06-23 2016-08-23 ノヴォ ノルディスク アー／エス 追加のジスルフィド結合を含有するインスリン類似体
EP2598522A4 (en) 2010-07-28 2014-11-12 Smartcells Inc RECOMBINANT LKTINE, BINDING POINT MODIFIED LECTIN AND APPLICATIONS THEREOF
US20140315797A1 (en) 2010-10-15 2014-10-23 Peter Madsen Novel N-Terminally Modified Insulin Derivatives
WO2012171994A1 (en) 2011-06-15 2012-12-20 Novo Nordisk A/S Multi substituted insulins
SG11201401835VA (en) 2011-10-27 2014-09-26 Univ Case Western Reserve Ultra-concentrated rapid-acting insulin analogue formulations
CN103443122B (zh) 2011-12-15 2016-05-11 上海恒瑞医药有限公司 人胰岛素类似物及其酰化衍生物
EP2970511B1 (en) 2013-03-14 2020-09-30 Indiana University Research and Technology Corporation Insulin-incretin conjugates
MX366852B (es) 2013-10-04 2019-07-25 Merck Sharp & Dohme Conjugados de insulina sensibles a glucosa.
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
AU2016311283B2 (en) 2015-08-25 2020-10-08 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
EP3341401A1 (en) * 2015-08-25 2018-07-04 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
CN105440125B (zh) 2015-11-25 2019-09-24 华润昂德生物药业有限公司 地特胰岛素或其类似物的制备方法
EP3740212A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
CN114787184A (zh) 2019-12-11 2022-07-22 诺和诺德股份有限公司 新型胰岛素类似物及其用途

Also Published As

Publication number Publication date
HRP20241042T1 (hr) 2024-11-08
PT4073097T (pt) 2024-08-16
KR20210141748A (ko) 2021-11-23
RS65822B1 (sr) 2024-09-30
MY208364A (en) 2025-05-01
KR102427426B1 (ko) 2022-08-01
PH12022551094A1 (en) 2024-06-24
JP2021091685A (ja) 2021-06-17
CO2022007273A2 (es) 2022-08-19
US20230192801A1 (en) 2023-06-22
FI4073097T3 (fi) 2024-08-13
CN114787184A (zh) 2022-07-22
HUE067827T2 (hu) 2024-11-28
TWI773009B (zh) 2022-08-01
TW202136289A (zh) 2021-10-01
EP4480492A2 (en) 2024-12-25
EP4073097A1 (en) 2022-10-19
MA58093B1 (fr) 2024-09-30
AU2020402135A1 (en) 2022-06-02
EP4480492A3 (en) 2025-03-19
BR112022009510A2 (pt) 2022-08-16
US12122818B2 (en) 2024-10-22
IL319162A (en) 2025-04-01
JP6995284B2 (ja) 2022-01-14
US20240141011A1 (en) 2024-05-02
CA3159114A1 (en) 2021-06-17
ES2985989T3 (es) 2024-11-08
EP4073097B1 (en) 2024-07-03
US12152063B2 (en) 2024-11-26
MX2022006251A (es) 2022-06-22
US11498951B2 (en) 2022-11-15
WO2021116292A1 (en) 2021-06-17
SI4073097T1 (sl) 2024-09-30
LT4073097T (lt) 2024-09-10
JP2021119193A (ja) 2021-08-12
DK4073097T3 (da) 2024-08-19
PE20221260A1 (es) 2022-08-16
IL292762A (en) 2022-07-01
PL4073097T3 (pl) 2024-10-28
US20210179685A1 (en) 2021-06-17
MX2023000398A (es) 2023-02-02
AR120717A1 (es) 2022-03-09
IL292762B2 (en) 2025-10-01
IL292762B1 (en) 2025-06-01

Similar Documents

Publication Publication Date Title
CL2023000086A1 (es) Análogos de insulina novedosos y usos de estos(div 202201400)
CO2019006017A2 (es) Composiciones farmacéuticas que contienen insulina
AR099569A1 (es) Derivados de insulina y los usos médicos de estos
AR106364A1 (es) Derivados de insulina y sus usos médicos
MX2019007071A (es) Novedosos derivados del acido fenilpropionico y usos de los mismos.
CL2022003187A1 (es) Compuestos de insulina acilada de acción temporal prolongada
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
MX2019014086A (es) Compuesto de insulina acilada.
BR112014004845A2 (pt) pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
AR116605A1 (es) Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a)
MX2022014924A (es) Moduladores de il-17a.
CO2020002500A2 (es) Análogos de insulina acilados novedosos y usos de estos
MX2021004566A (es) Compuestos terapeuticos.
BR112017010602A2 (pt) análogos de ureia ligados em ponte substituídos como moduladores de sirtuína
CO2021000229A2 (es) Compuestos de pirazol e imidazol para la inhibición de il-17 y rorgamma
BR112018017167A2 (pt) titulação de cebranopadol
UY38199A (es) Compuestos de hexapéptidos cíclicos con actividad antimalárica
UY27193A1 (es) Glicina, n-(n-l-y glutamil-3-(nitrosotio)-l-valil) y sus aplicaciones